Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G. Kerbrat A, et al. Among authors: lallement f. J Neurol Sci. 2011 Sep 15;308(1-2):98-102. doi: 10.1016/j.jns.2011.05.043. Epub 2011 Jun 12. J Neurol Sci. 2011. PMID: 21665227
Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Callens A, Leblanc S, Le Page E, Edan G, Jourdain A, Coustans M, Wiertlewski S, Laplaud D, Videt D, Lallement F, Leray E, Michel L. Callens A, et al. Among authors: lallement f. Mult Scler Relat Disord. 2022 Oct;66:104066. doi: 10.1016/j.msard.2022.104066. Epub 2022 Jul 22. Mult Scler Relat Disord. 2022. PMID: 35908450 Free article.
Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.
Michel M, Le Page E, Laplaud DA, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Coustans M, Edan G, Chevreul K, Veillard D; West Network for Excellence in Neuroscience; COPOUSEP investigators. Michel M, et al. Rev Neurol (Paris). 2022 Mar;178(3):241-248. doi: 10.1016/j.neurol.2021.06.009. Epub 2021 Sep 28. Rev Neurol (Paris). 2022. PMID: 34598781 Clinical Trial.
Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.
Papeix C, Castelnovo G, Leray E, Coustans M, Levy P, Visy JM, Kobelt G, Lamy F, Allaf B, Heintzmann F, Chouette I, Raponi E, Durand B, Grevat E, Kamar D, Debouverie M, Lebrun-Frenay C; Virgile Study Group. Papeix C, et al. Neurol Ther. 2022 Jun;11(2):633-658. doi: 10.1007/s40120-022-00334-y. Epub 2022 Feb 11. Neurol Ther. 2022. PMID: 35147904 Free PMC article.
Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?
Drapier D, Drapier S, Sauleau P, Haegelen C, Raoul S, Biseul I, Peron J, Lallement F, Rivier I, Reymann JM, Edan G, Verin M, Millet B. Drapier D, et al. Among authors: lallement f. J Neurol. 2006 Aug;253(8):1083-91. doi: 10.1007/s00415-006-0177-0. Epub 2006 Apr 10. J Neurol. 2006. PMID: 16607469 Clinical Trial.
Fear recognition is impaired by subthalamic nucleus stimulation in Parkinson's disease.
Biseul I, Sauleau P, Haegelen C, Trebon P, Drapier D, Raoul S, Drapier S, Lallement F, Rivier I, Lajat Y, Verin M. Biseul I, et al. Among authors: lallement f. Neuropsychologia. 2005;43(7):1054-9. doi: 10.1016/j.neuropsychologia.2004.10.006. Epub 2004 Dec 30. Neuropsychologia. 2005. PMID: 15769491 Clinical Trial.
17 results